Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2022 vs. Q4 2021
How the institutions holding Oruka Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 21 | 22 | +1 |
| Shares | 1.12M | 1.13M | +12.3K (+1.1%) |
| Value | $2.41M | $2.60M | +$196.0K (+8.1%) |
New holders (5)
Institutions that held Oruka Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 23,874 | $55.0K | 0.00% |
| Bridgeway Capital Management, LLC | 21,948 | $50.0K | 0.00% |
| Marquette Asset Management, LLC | 17,318 | $40.0K | 0.01% |
| Citigroup Inc | 1,790 | $4.00K | 0.00% |
| JPMorgan Chase & Co | 675 | $2.00K | 0.00% |
Sold out (4)
Institutions that held Oruka Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Acadian Asset Management LLC | 57,822 | $123.0K |
| Susquehanna International Group, LLP | 32,067 | $69.0K |
| Morgan Stanley | 1 | $0 |
| Tyler-Stone Wealth Management | 50 | $0 |